Cook H T, Singh S J, Wembridge D E, Smith J, Tam F W, Pusey C D
Department of Histopathology, Imperial College School of Medicine, Hammersmith Hospital, London, England, United Kingdom.
Kidney Int. 1999 Apr;55(4):1319-26. doi: 10.1046/j.1523-1755.1999.00354.x.
Activated macrophages play a central role in crescentic glomerulonephritis. Interleukin-4 (IL-4) down-regulates many macrophage proinflammatory activities. We therefore studied the effect of IL-4 on glomerular injury in a model of crescentic glomerulonephritis in the Wistar Kyoto rat.
Glomerulonephritis was induced by i.v. administration of rabbit antirat glomerular basement membrane antiserum (nephrotoxic serum, NTS). In experiment 1, IL-4 was given from two hours before NTS until day 6. In experiment 2, rats were treated from day 0 to 7 and were then monitored until killed on day 28. In experiment 3, IL-4 was given from day 4 to 7.
Continuous IL-4 treatment (experiment 1) significantly (P = 0.001) reduced proteinuria (3 +/- 1 mg per 24 hr vs. 56 +/- 7), fibrinoid necrosis (0.06 +/- 0.04 quadrants/glomulus vs. 1.2 +/- 0.1), macrophage infiltration (6.7 +/- 2.6 cells/glom vs. 33 +/- 2.5), CD8+ cells (1.5 +/- 0.6 cells/glom vs. 6.2 +/- 1.1), inducible nitric oxide synthase positive cells (0.04 +/- 0.04 cells/glom vs. 3.7 +/- 0.6), proliferating cell nuclear antigen positive cells (3.2 +/- 1 cells/glom vs. 15 +/- 2.3), and glomerular intercellular adhesion molecule-1 expression. Follow-up after seven days of treatment (experiment 2) showed that at four weeks, creatinine clearance was higher in treated rats (1.1 +/- 0.1 ml/min vs. 0.4 +/- 01, P = 0.011), and both glomerular scarring (P = 0.006) and tubular atrophy (P = 0.006) were less. Delayed treatment (experiment 3) reduced proteinuria (41 +/- 5 mg per 24 hr vs. 97 +/- 9, P = 0.004) and fibrinoid necrosis (0.39 +/- 0.05 quadrants/glom vs. 1.6 +/- 0.1, P = 0.004). There was no difference in macrophage infiltration, but inducible nitric oxide synthase positive cells were reduced (0.6 +/- 0.1 cells/glom vs. 1.8 +/- 0.4, P = 0.01) as were ED3+ cells (0.18 +/- 0.06 cells/glom vs. 1.86 +/- 0.21, P = 0.004).
In this model of crescentic glomerulonephritis, early IL-4 treatment abolished proteinuria and markedly reduced glomerular inflammation. If treatment was stopped after seven days, there was continuing benefit on glomerular and tubulointerstitial scarring and creatinine clearance at four weeks. If treatment was delayed until inflammation was established, there was still a reduction of injury, but without an alteration of macrophage numbers, suggesting that IL-4 may be acting, in part, to reduce macrophage activation.
活化的巨噬细胞在新月体性肾小球肾炎中起核心作用。白细胞介素-4(IL-4)可下调多种巨噬细胞促炎活性。因此,我们在Wistar Kyoto大鼠新月体性肾小球肾炎模型中研究了IL-4对肾小球损伤的影响。
通过静脉注射兔抗大鼠肾小球基底膜抗血清(肾毒性血清,NTS)诱导肾小球肾炎。在实验1中,从注射NTS前两小时至第6天给予IL-4。在实验2中,大鼠从第0天至第7天接受治疗,然后监测至第28天处死。在实验3中,从第4天至第7天给予IL-4。
持续给予IL-4治疗(实验1)显著(P = 0.001)降低蛋白尿(每24小时3±1mg对56±7)、纤维蛋白样坏死(0.06±0.04象限/肾小球对1.2±0.1)、巨噬细胞浸润(6.7±2.6个细胞/肾小球对33±2.5)、CD8 +细胞(1.5±0.6个细胞/肾小球对6.2±1.1)、诱导型一氧化氮合酶阳性细胞(0.04±0.04个细胞/肾小球对3.7±0.6)、增殖细胞核抗原阳性细胞(3.2±1个细胞/肾小球对15±2.3)以及肾小球细胞间黏附分子-1表达。治疗7天后随访(实验2)显示,在4周时,治疗组大鼠的肌酐清除率更高(1.1±0.1ml/分钟对0.4±
0.1,P = 0.011),肾小球瘢痕形成(P = 0.006)和肾小管萎缩(P = 0.006)均减轻。延迟治疗(实验3)降低了蛋白尿(每24小时41±5mg对97±9,P = 0.004)和纤维蛋白样坏死(0.39±0.05象限/肾小球对1.6±0.1,P = 0.004)。巨噬细胞浸润无差异,但诱导型一氧化氮合酶阳性细胞减少(0.6±0.1个细胞/肾小球对1.8±0.4,P = 0.01),ED3 +细胞也减少(0.18±0.06个细胞/肾小球对1.86±0.21,P = 0.004)。
在该新月体性肾小球肾炎模型中,早期给予IL-4治疗可消除蛋白尿并显著减轻肾小球炎症。如果在7天后停止治疗,4周时对肾小球和肾小管间质瘢痕形成以及肌酐清除率仍有持续益处。如果治疗延迟至炎症形成后,损伤仍有减轻,但巨噬细胞数量无改变,提示IL-4可能部分通过减少巨噬细胞活化发挥作用。